MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC
MTAP IHC seems to be better suited than OPA-NGS to assess the MTAP status in NSCLC, especially as the MTAP gene is not specifically covered within this panel. CDKN2A loss is not a reliable MTAP loss surrogate, as it overestimates MTAP loss in more than 25% of the cases in the TCGA cohort.
Authors
- Lukas Bubendorf (ORCID: https://orcid.org/0000-0001-5970-1803)
- Obinna Chijioke (ORCID: https://orcid.org/0000-0003-4247-5947)
- David König (ORCID: https://orcid.org/0000-0003-3559-6855)
- Luca Roma (ORCID: https://orcid.org/0000-0003-4632-5372)
- Tatjana Vlajnic (ORCID: https://orcid.org/0000-0002-1067-6771)
- Spasenija Savic-Prince
- Ilaria Alborelli (ORCID: https://orcid.org/0000-0001-7849-3958)
- Sebastian Ott
- Magdalena M. Brune (ORCID: https://orcid.org/0000-0002-9236-1377)
- Nikolaus Deigendesch (ORCID: https://orcid.org/0000-0002-6036-3327)
- Petra Hirschmann
- Martin Zacharias (ORCID: https://orcid.org/0000-0003-3021-1047)
- Lenard Bubendorf
- Julian Pollinger
Institutions
- University of Basel (CH)
- Medical University of Graz (AT)
- University Hospital of Bern (CH)
- University Hospital of Basel (CH)
- St. Claraspital (CH)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.jtho.2025.08.014
- Citations
- 2
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 2.09